Megatron S4 from Geuder delivers flexibility and mobility

Article

Geuder has launched the Megatron S4 system, an upgrade on the company?s Megatron S3, which has sold 700 units worldwide since its launch in 2001. “The launch of the S4 marks the successful end of about three years work,”said Dirk Mittnacht, product manager systems for Geuder.

Geuder has launched the Megatron S4 system, an upgrade on the company’s Megatron S3, which has sold 700 units worldwide since its launch in 2001. “The launch of the S4 marks the successful end of about three years work,”said Dirk Mittnacht, product manager systems for Geuder.

Mittnacht highlighted the increased flexibility of the Megatron. There are three options for creating vacuums from its dual-pump system – classic vacuum build-up and efficient vacuum build-up with venturi-effect mode, both controlled via a peristaltic pump; and immediate vacuum build-up with venturi-mode where rise-time is controlled via a direct control pump. A programmable footswitch offers linear, fixed or exponential control of all vacuum modes.

The new system also works across both anterior and posterior segment surgeries. “This compares well with competitive systems that handle anterior or posterior. The S4 handles both providing great flexibility when hospital schedules switch, for example,” said Mittnacht.

Measuring 420mm x 420mm x 370mm and weighing just 25Kg the S4 system also delivers increased mobility. Its unPLUG features include an internal compressor to provide consistent quality of compressed air without the need for connection to an external source. An optional UPS allows the system to be disconnected temporarily from external power supplies, making it possible for the system to be moved between operating rooms while it is still running.

An integrated intraocular LED light source in a handpiece, ocuLED, has been designed to deliver consistent light quality without the additional cost or constraints of a central light source.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.